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In Brief
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in CIN cells. This is accompanied by
alterations in mitotic signaling pathways
that are consistent with adaptive
resistance. These results shed light on
drug resistance in CIN cells and highlight
the underappreciated role of CIN in
cancer relapse.
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Karyotype diversity is a hallmark of solid tumors that
contributes to intratumor heterogeneity. This diver-
sity is generated by persistent chromosome mis-
segregation associated with chromosomal instability
(CIN). CIN correlates with tumor relapse and is
thought to promote drug resistance by creating a
vast genomic landscape through which karyotypi-
cally unique clones survive lethal drug selection.
We explore this proposition using a small molecule
(UMK57) that suppresses chromosome mis-segre-
gation in CIN cancer cells by potentiating the activity
of the kinesin-13 protein MCAK. Sublethal doses of
UMK57 destabilize kinetochore-microtubule (k-MT)
attachments duringmitosis to increase chromosome
segregation fidelity. Surprisingly, chromosome mis-
segregation rebounds in UMK57-treated cancer cells
within a few days. This rapid relapse is driven by al-
terations in the Aurora B signaling pathway that
hyper-stabilize k-MT attachments and is reversible
following UMK57 removal. Thus, cancer cells display
adaptive resistance to therapies targeting CIN
through rapid and reversible changes to mitotic
signaling networks.INTRODUCTION
Aneuploidy is a hallmark of solid tumors (Luo et al., 2009) and
commonly arises in tumors through the frequent mis-segrega-
tion of whole chromosomes as a consequence of chromosomal
instability (CIN) (Geigl et al., 2008; Lengauer et al., 1997). Persis-
tent chromosome mis-segregation is a major driver of intra-tu-
mor heterogeneity (Heppner, 1984), a genomic change that is
proposed to allow cells to acquire new phenotypes (Duesberg
et al., 2000; Gerlinger and Swanton, 2010). Accordingly, CIN
positively correlates with poor patient prognosis (Bakhoum
et al., 2011), multidrug resistance (Lee et al., 2011), and tumor
relapse (Sotillo et al., 2010). The prevailing model posits that
CIN generates a genomic landscape from which clones andCell Rep
This is an open access article under the CC BY-Nsub-clones with specific karyotypes emerge from the population
through survival of targeted therapy and/or other selective pres-
sures (Greaves and Maley, 2012). Directly testing this model
requires the development of tools that specifically suppress
CIN in human cancer cells.
The root cause of CIN is the persistence of errors in kineto-
chore-microtubule (k-MT) attachments in mitosis (Thompson
and Compton, 2008). Errors in k-MT attachment arise spontane-
ously during mitosis and are efficiently corrected in diploid cells
to preserve genome integrity. The correction process relies on
the frequent detachment of microtubules from kinetochores
to allow for microtubules with the proper orientation to make
attachments. It was previously demonstrated that many CIN can-
cer cells have hyper-stable k-MT attachments and fail to effi-
ciently correct k-MT attachment errors (Bakhoum et al., 2009a).
Importantly, strategically destabilizing k-MT attachments by
overexpressing the microtubule-destabilizing kinesin-13 proteins
Kif2b and MCAK suppresses CIN in cancer cells and establishes
a causative relationship between the stability of k-MT attach-
ments and the rate of chromosome mis-segregation (Bakhoum
et al., 2009a, 2009b, 2014; Kleyman et al., 2014). These data pro-
vide proof of concept for a strategy to suppress CIN in human
cancer cells. Unfortunately, this strategy is severely limited by
the requirement for protein overexpression in tumor cells. To
overcome this technical limitation and to examine how cancer
cells respond to the suppression of CIN, we examine the effects
of a cell-permeable small molecule that potentiates the microtu-
bule depolymerizing activity of the kinesin-13 protein MCAK.RESULTS AND DISCUSSION
UMK57 Potentiates MCAK Activity
Current strategies for the suppression CIN in cancer cells rely on
the manipulation of proteins involved in the regulation of k-MT
attachments during mitosis (Bakhoum et al., 2009b; Ertych
et al., 2014), which prove to be limiting outside of cell culture.
To overcome these limitations, a high-throughput screen was
performed to identify small molecules that modulate the activ-
ities of kinesin-13 proteins (Talje et al., 2014). This screen identi-
fied a kinesin-13 inhibitor that was previously reported (Talje
et al., 2014). This screen also identified a family of com-
pounds that potentiate the microtubule depolymerizing activityorts 17, 1755–1763, November 8, 2016 ª 2016 The Authors. 1755
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. UMK57 Targets MCAK In Vivo but Does Not Alter Its Levels or Localization in Cells
(A) Percentage of mitotic cells in prometaphase, metaphase, or anaphase in cells treated with DMSO or increasing concentrations of UMK57 for <1 hr (nR 200
mitotic cells). For each concentration of UMK57, the percentage of anaphases with lagging chromosomes is shown below (nR 150 anaphases).
(B) Lagging chromosome rates of U2OS cells treated with DMSO or UMK95, a chemical probe that is structurally similar to UMK57 but inactive in vitro (nR 150
anaphases); n.s., p > 0.05 using Fisher’s exact two-tailed test.
(legend continued on next page)
1756 Cell Reports 17, 1755–1763, November 8, 2016
of kinesin-13 proteins in vitro, and the complete characterization
of how these compounds affect the biochemistry of kinesin-13
proteins in vitro will be provided elsewhere. Here, we focus on
the effects of one of these compounds (UMK57) on chromosome
segregation during mitosis in vivo. We focused on UMK57
because it shows no inhibitory effect on the ATPase activity of
any kinesins tested (Figure S1A) but specifically enhances
MCAK-dependent microtubule depolymerization as measured
using in vitro microtubule sedimentation (Figure S1B) and micro-
scopy (Figure S1C) assays. Additionally, UMK57 inhibits cell
proliferation in a dose-dependent manner (Figure S1D). In
contrast, a chemically related analog differing only in one
chemical group (UMK95) has no effect on MCAK-mediated
microtubule depolymerization (Figure S1B) or cell proliferation
(Figure S1D), demonstrating the potency and specificity of
UMK57 (Figures S1E and S1F).
Titration experiments in U2OS cells demonstrate that 100 nM
UMK57 is the optimal dose to achieve the maximal effect on
the fidelity of chromosome segregation without significantly
affecting mitotic progression (Figure 1A); therefore, all treat-
ments were done at this concentration, unless stated otherwise.
Treatment of cells with UMK95, a chemically related but inactive
compound (Figure S1F), shows no detectable effect on chromo-
some segregation (Figure 1B), underscoring the specificity of
UMK57 (Arrowsmith et al., 2015) (Figure S1E). It is important to
note that treatment of cells with 100 nM UMK57 does not alter
total MCAK levels (Figure 1C), MCAK localization, or spindle
organization at different stages of mitosis (Figures 1D). Also,
very few UMK57-treated cells transiently expressing GFP or
GFP-Kif2b show discernible defects in chromosome alignment
or spindle bipolarity (Figures 1E and 1F). In contrast, a sub-
stantial fraction of UMK57-treated cells transiently expressing
GFP-MCAK display defects in chromosome alignment and spin-
dle organization, indicating that MCAK overexpression renders
cells hypersensitive to UMK57 (Figures 1E and 1F). In addition,
UMK57 reduces the rate of chromosome mis-segregation in
control and Kif2b-depleted cells (Figures 1G and 1H). However,
there is no change in the rate of chromosome mis-segregation
in MCAK-depleted cells (Figures 1G and 1H). This indicates
that the effects of UMK57 in mitosis are dependent on the pres-
ence of MCAK.
UMK57 Suppresses CIN in Human Cancer Cells
To determine the effect of UMK57 on chromosome segregation
in different human cell lines, we quantified lagging chromosome
rates in anaphase in CIN cancer lines (U2OS, HeLa, and SW-620)
and in non-transformed diploid cell lines (hTERT-immortalized(C) Quantitative western blot of mitotic U2OS cell extracts treated with MG132 fo
with DMSO, ZM447439, or UMK57 for 1 hr and blotted for total MCAK and a-tubul
(D) U2OS cells treated with DMSO or UMK57 for <1 hr and then fixed and sta
a-tubulin. Insets represent 53 magnifications of selected regions (further contra
(E) U2OS cells transiently overexpressing GFP, GFP-Kif2b, or GFP-MCAKwere tre
and ACA. Scale bar, 5 mm.
(F) Percentage of prometaphase cells with defects in spindle organization in cel
UMK57 (n > 150 prometaphase cells).
(G) Total cell lysates of Mock-, Kif2b-, and MCAK-depleted U2OS cells were imm
(H) Quantification of lagging chromosome rates inMock-, Kif2b-, or MCAK-deplet
bars represent SEM. **p% 0.01; n.s., p > 0.05 using Fisher’s exact two-tailed teRPE-1 and BJ). Treatment with UMK57 significantly reduces
lagging chromosome rates in all cancer cell lines tested but
has no effect on chromosome segregation in the non-trans-
formed diploid cell lines (Figures 2A and 2B). Given that many
lagging chromosomes in anaphase can segregate to the correct
daughter cell (Thompson and Compton, 2011), we tested
whether UMK57 treatment also reduces the rate of chromosome
non-disjunction. We measured the fate of sister chromatids of a
single chromosome in HCT116 cells recovering from a monas-
trol-induced mitotic arrest using previously described methods
(Lampson and Kapoor, 2005; Thompson and Compton, 2008,
2011). Cells treated with UMK57 display a significantly lower
rate of chromosome non-disjunction than control cells (Figures
2C and 2D).
Next, we quantified the stability of k-MT attachments in
UMK57-treated U2OS cells by measuring the rate of dissipation
of fluorescence after photoactivation of GFP-tubulin (Zhai et al.,
1995). The stability of k-MT attachments during metaphase in
mitotic cells treated with UMK57 is reduced by more than 35%
when compared to control cells, consistent with the potentiation
of the microtubule depolymerase activity of MCAK (Figures 2E
and S2A–S2C). There is no significant change in the stability of
k-MT attachments in prometaphase, which is in agreement
with previous reports indicating that MCAK preferentially desta-
bilizes metaphase k-MTs in this cell line (Bakhoum et al., 2009b).
Moreover, there are no significant differences in the fractions of
microtubules in the stable (k-MT) versus unstable (non-k-MT)
populations (Figure S2D) or in the turnover rate of the unstable
population in UMK57-treated cells (Figure S2E). Despite the
destabilization of k-MTs during metaphase, UMK57 treatment
at this dose does not significantly alter mitotic progression (Fig-
ure 1A) but induces a subtle yet significant reduction in the inter-
kinetochore distance of aligned kinetochore pairs (Figure 2F).
However, UMK57 treatment does not affect chromosome
bi-orientation or the spindle assembly checkpoint as judged
by the localization patterns of Aurora B kinase (Figure S2F) or as-
trin (Figure S2G) and the levels of the mitotic checkpoint protein
BubR1 at kinetochores (Figures 2G and 2H). Furthermore, RPE-1
and U2OS cell lines display differential sensitivity to UMK57, but
not vinblastine, indicating that the effects of UMK57 are distinct
from a compound that directly targets tubulin (Figures S2H–
S2K). Collectively, these results demonstrate that UMK57 acts
through an MCAK-dependent process to specifically destabilize
k-MT attachments during metaphase and reduces chromosome
mis-segregation with little or no appreciable effects on other
mitotic processes. Thus, UMK57 is a small molecule that specif-
ically promotes the correction of k-MT attachment errors tor 4 hr to enrich the mitotic population and prevent mitotic exit and then treated
in. Numbers below indicate the relative quantities (percentage) for each protein.
ined to reveal DNA, anti-centromere antibody (ACA; blue), MCAK (green), or
sted for better visualization). Scale bar, 5 mm.
ated with UMK57 (100 nM) and then fixed and stained to reveal DNA, a-tubulin,
ls overexpressing GFP, GFP-Kif2b, or GFP-MCAK and treated with DMSO or
unoblotted for MCAK and a-tubulin (loading control).
ed cells incubated with DMSO or UMK57 for <1 hr (n > 100 anaphases). All error
st.
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Figure 2. UMK57 Reduces Lagging Chro-
mosome Rates in Human Cancer Cell Lines
by Destabilizing k-MT Attachments in
Metaphase
(A) Representative immunofluorescence image of
U2OS cells in anaphase treated with DMSO or
UMK57 for <1 hr and then fixed and stained to
reveal DNA (blue) and ACA (red). Inset represents
53 magnification of selected region (further con-
trasted for better visualization). Scale bar, 5mm.
(B) Percentage of lagging chromosomes in
anaphase in multiple cell lines after treatment
with DMSO or UMK57 for <1 hr (n > 300 ana-
phases). Error bars represent SD from three inde-
pendent experiments. *p% 0.05; **p% 0.01; n.s.,
p > 0.05 using Fisher’s exact two-tailed test.
(C) Representative immunofluorescence image
of segregation phenotypes in HCT116 cells ex-
pressing LacI-GFP with LacO arrays integrated
into a single chromosome that were fixed and
imaged after completion of cytokinesis. Scale
bar, 5 mm.
(D) Quantification of total mis-segregation events
in HCT116 cells expressing LacI-GFP with LacO
arrays integrated into a single chromosome sub-
jected to a monastrol washout into media con-
taining DMSO or UMK57 and allowed to complete
mitosis and re-enter interphase. Total mis-segre-
gation was quantified as depicted in panel (C)
(n > 600 pairs of daughter nuclei). **p% 0.01 using
Fisher’s exact two-tailed test.
(E) Calculated k-MT half-life in U2OS cells treated
with 5 mM MG132 (control) or 5 mM MG132 +
UMK57 (100 nM); n = 12–19 cells. Graph shows
mean ± SEM; **p% 0.01; n.s., p > 0.05 using two-
tailed t test.
(F) Quantification of inter-kinetochore distance as
measured by distance between Hec1 staining in
sister kinetochores in cells treated with DMSO or
UMK57. Red bars indicate the mean and red error
bars the SEM; n R 150 kinetochores; *p % 0.05;
n.s., p > 0.05 using two-tailed t test.
(G) Cells treated with DMSO or UMK57 for <1 hr
and then fixed and stained to reveal DNA (blue),
BubR1 (green), and Hec1. Insets represent 53
magnifications of selected regions (further con-
trasted for better visualization). Scale bar, 5 mm.
(H) Quantification of BubR1 levels at kinetochores
(normalized to Hec1) in U2OS cells treated with
UMK57 (100 nM) for <1 hr as quantified by immu-
nofluorescence. nR 150 kinetochores from 10–20
cells; n.s., p > 0.05 using two-tailed t test. All error
bars represent SEM.suppress chromosomemis-segregation in CIN cancer cells, with
no detectable effects on non-transformed diploid cells.
Resistance to UMK57 Treatment Arises Rapidly
The gold standard for assaying CIN is through the measurement
of karyotypic diversity in colonies derived from single cells where
chromosomally stable cells generate karyotypically homoge-
neous populations and CIN cells generate karyotypically hetero-
geneous populations (Bakhoum et al., 2009b; Lengauer et al.,
1997; Thompson and Compton, 2008). To determine if UMK57
suppresses CIN in this context, we used fluorescence in situ1758 Cell Reports 17, 1755–1763, November 8, 2016hybridization (FISH) to determine the modal chromosome num-
ber for two different chromosomes and scored the percentage
of cells that deviate from that mode in two independent colonies
grown from single cells for each condition. Non-transformed
RPE-1 cells maintain stable diploid karyotypes, and the fraction
of cells that deviate from the modal chromosome copy number
within each colony is very low and insensitive to UMK57 treat-
ment (Figures 3A and 3B). U2OS cells are CIN, and the fraction
of cells that deviate from the modal chromosome copy number
within each colony is high. Surprisingly, treatment of U2OS cells
with UMK57 continuously during colony growth (6–8 weeks) did
Figure 3. Long-Term Exposure to UMK57
Results in Decreased Responsiveness to
UMK57-Mediated Suppression of CIN
(A) Example of FISH data from U2OS single-cell
clones fixed and stained with DNA (blue) to visu-
alize nuclei and with probes specific for centro-
meric a-satellite DNA of chromosomes 2 (green)
and 3 (red). White arrows indicate cells whose
chromosome copy number deviates from the
modal chromosome number (Chr. 2, mode of 4;
Chr. 3, mode of 5). Scale bar, 5 mm.
(B) Percentage of nuclei that deviate from the
modal chromosome number in RPE-1 or U2OS
single-cell clones grown in the presence of DMSO
or UMK57. Chromosome copy number quantified
for chromosomes 2 and 3 (n > 300 nuclei).
(C) Media with DMSO or UMK57 was prepared
and added to U2OS cells at time 0. Cells were
fixed and stained every 24 hr and lagging chro-
mosome rates quantified every 24 hr. *p % 0.05;
**p% 0.01; n.s., p > 0.05 using Fisher’s exact two-
tailed test. Media with DMSO, UMK57, or
UMK57 + verapamil (MDR1 inhibitor) was pre-
pared and added to cells at time 0.
(D–F) Cells were fixed and stained at <1 hr and
72 hr and lagging chromosome rates quantified for
(D) U2OS cells (n > 300), (E) HeLa cells (n > 300),
and (F) SW-620 cells (n > 200). Total lagging
chromosome rates were pooled from two inde-
pendent experiments; *p% 0.05; **p% 0.01; n.s.,
p > 0.05 using Fisher’s exact two-tailed test. All
error bars represent SEM.not reduce the fraction of cells that deviate from the modal chro-
mosome copy number within each colony (Figures 3A and 3B).
Thus, CIN cells treated with UMK57 for extended time periods
maintain karyotypic heterogeneity, despite the fact that it sup-
presses chromosome mis-segregation in this cell line when
measured immediately (Figures 2A–2D). This cellular response
was not observed previously when CINwas suppressed by over-
expression of MCAK or Kif2b (Bakhoum et al., 2009b), indicating
a distinction between protein overexpression and chemical
enhancement of protein activity as methods to suppress CIN
in cancer cells.
Serial transfer of culture media over multiple days followed by
immediate quantification of chromosome segregation defects in
U2OS cells verifies that UMK57 retains biological activity in cul-
ture media for up to 120 hr (Figure S3A). Nevertheless, laggingCell Repochromosome rates in cells treated with
UMK57 return to control levels within
72 hr (Figure 3C), and this phenomenon
was also observed if media containing
UMK57 was renewed every 24 hr (Fig-
ure S3B). This time-dependent decrease
in responsiveness to UMK57 was also
observed in multiple CIN cancer cell lines
(Figures 3D–3F). In addition, verapamil,
a potent inhibitor of the multidrug efflux
pump encoded by the MDR1 gene, was
effective at enhancing the response ofthese cells to doxorubicin (Figures S3C and S3D), but it did not
significantly alter the decrease in responsiveness to UMK57
(Figures 3D–3F). This suggests that resistance to UMK57 occurs
independently of multidrug efflux pump activity.
Aurora B Kinase Influences the Rate of Resistance to
UMK57
We then focused on the events that change in mitotic cells
during extended treatment with UMK57. Kinetochore-micro-
tubule attachment stability in metaphase cells is reduced
equivalently in cells treated with UMK57 for 1 hr or 72–
120 hr, thus verifying the persistent UMK57-dependent
MCAK activation during extended treatment (Figures 2E
and 4A). Accordingly, the quantity of phosphorylated MCAK
at centromeres does not change between cells treated withrts 17, 1755–1763, November 8, 2016 1759
Figure 4. Rate of Adaptive Resistance in
UMK57-Treated Cells Is Dependent on
Aurora B Activity
(A) Calculated k-MT stability for U2OS cells
treated with UMK57 for 72–120 hr or 6–8 weeks or
for 6–8 weeks followed by UMK57 washout (72–
120 hr post-washout). n = 10–42 cells. Graph
shows mean ± SEM. Statistical analysis per-
formed between control and UMK57-treated cells
for eachmitotic phase. *p% 0.05; **p% 0.01 using
two-tailed t test.
(B) Quantification of the relative levels of phospho-
MCAK Ser95 at kinetochores and centromeres in
U2OS cells treated with UMK57 for <1 hr or >72 hr
as quantified by immunofluorescence.
(C) Representative image of U2OS cells in prom-
etaphase and metaphase treated with DMSO or
UMK57 for 72 hr, fixed and stained to reveal DNA
(blue), phospho-Aurora B Thr232 (green), and
ACA. Scale bar, 5 mm.
(D) Quantification of phospho-Aurora B Thr232
at kinetochores and centromeres in U2OS cells
treated with UMK57 for <1 hr or >72 hr as
quantified by immunofluorescence. n R 300 ki-
netochores from 10–20 cells for quantification
of phospho-MCAK S95 and phospho-Aurora B
Thr232. **p % 0.0; n.s., p > 0.05 using two-tailed
t test.
(E) Media with DMSO or ZM447439 + UMK57 was
prepared and added to cells at time 0. Cells were
fixed and stained at <1 hr, 72 hr, 96 hr, and 120 hr
and lagging chromosome rates quantified for each
time point (n R 150 anaphases). *p % 0.05; n.s.,
p > 0.05 using Fisher’s exact two-tailed test.
(F) Conceptual model for adaptive and acquired
drug resistance in CIN cancer cells. Non-trans-
formed diploid cells are non-adaptable and
genetically homogeneous. Upon oncogenic
transformation, the resulting tumor cells become
both adaptable to stressful conditions and karyo-
typically heterogeneous through chromosomal
instability. Adaptive resistance arises through the
rapid and reversible changes in intracellular
signaling networks within the genetically hetero-
geneous population. Acquired drug resistance
occurs through the selection of rare, genetically
unique cells from the population of heterogeneous
cells. These mechanisms of resistance are not
mutually exclusive.
All error bars represent SEM.UMK57 for 1 hr or >72 hr (Figure 4B), suggesting MCAK
levels remain unchanged within this time frame. Moreover,
extended treatment with UMK57 did not change the fractions
of microtubules in the stable (k-MT) versus unstable (non-k-
MT) populations or in the turnover rate of the unstable popu-
lation in UMK57-treated cells (Figures S3E–S3H). In contrast,
k-MT attachment stability in prometaphase cells significantly
increases upon exposure to UMK57 for 72–120 hr or 6–
8 weeks (Figure 4A), the latter being a time frame that mimics
the clonal cell growth assay (Figures 3A and 3B). Strikingly,
these changes in k-MT attachment stability in response
to UMK57 treatment are reversible upon UMK57 removal
(Figure 4A).1760 Cell Reports 17, 1755–1763, November 8, 2016In addition to the stabilization of k-MT attachments in prome-
taphase, there is a substantial reduction in active Aurora B
kinase at centromeres in cells treated with UMK57 for >72 hr
(Figures 4C and 4D). However, this did not lead to corresponding
changes in substrate phosphorylation, as phopsho-KNL1 levels
were specifically increased at unaligned kinetochores (Fig-
ure S3I) and there were no changes in phospho-Hec1 levels
(Figure S3J). This suggests that the Aurora B signaling network
(e.g., the spatially regulated activities of both the kinase and
the counteracting phosphatases) is altered in cells exposed to
UMK57 for >72 hr. Thus, the capacity of UMK57 to initially
improve chromosome segregation fidelity in CIN cancer cells
by destabilizing k-MT attachments in metaphase is superseded
after just a few days of UMK57 treatment by changes in Aurora B
kinase signaling and hyperstabilization of k-MT attachments
in prometaphase. Consistently, single-cell clones grown contin-
uously in the presence of UMK57 display reduced sensitivity
to the Aurora B inhibitor ZM447439 but show no changes in
sensitivity to other compounds such as doxorubicin, Taxol,
vinblastine, or BI-2536 (Figures S4A–S4G).
Next, we dampened Aurora B kinase signaling using the inhib-
itor ZM447439 at a dose (250 nM) sufficient to partially inhibit
Aurora B kinase activity as determined by the effect on phos-
phorylation of histone H3 at Ser10 in early prometaphase (Fig-
ure S4H). Partial inhibition of Aurora B kinase signaling does
not increase lagging chromosome rates or affect the ability of
UMK57 to reduce lagging chromosome rates in U2OS cells
when measured within 1 hr (Figure S4I). However, partial inhibi-
tion of Aurora B kinase activity prevents cells from regaining high
levels of lagging chromosomes in anaphase after treatment with
UMK57 for 72 hr (Figures 4E and S4J). Partial Aurora B kinase
inhibition also delayed the emergence of resistance to UMK57
in SW-620 cells (Figure S4K) but did not do so in HeLa cells (Fig-
ure S4L). This demonstrates that changes in the Aurora B kinase
signaling pathway are a commonmeans to develop resistance to
UMK57 and that the full dynamic range of Aurora B kinase
signaling is required for the emergence of this resistance within
a 72-hr time frame. The effect of partial Aurora B kinase inhibition
in preventing resistance to UMK57 was only transient, because
cells ultimately regained high rates of lagging chromosomes in
anaphase by 96 hr in the presence of UMK57 and the Aurora B
kinase inhibitor (Figures 4E and S4K). Thus, cells achieve resis-
tance to UMK57 through multiple pathways, suggesting that
there is strong selective pressure to maintain high levels of
chromosome mis-segregation in CIN cancer cells.
This work demonstrates that CIN cancer cells can systemati-
cally alter mitotic signaling pathways to generate resistance to
therapies designed to target the specific mitotic defects that
cause persistent chromosome mis-segregation. Emergence of
resistance through rapid and reversible alterations of cellular
signaling pathways is defined as adaptive resistance (Figure 4F).
This is distinct from acquired resistance (Duesberg et al., 2000;
Gerlinger and Swanton, 2010; Gottesman, 2002) that arises
through the selection of rare, genetically unique cells from het-
erogeneous populations (Figure 4F). Other distinguishing fea-
tures of cells that become drug resistant through an adaptive
mechanism is the retention of genome complexity in the popula-
tion (Figure 4F), aswe observed in our FISH experiments (Figures
3A and 3B), and the emergence of resistance at sublethal doses
(Figures 3D–3F and S2A). However, it is likely that both adaptive
and acquired resistance contribute to drug resistance in a tumor
cell population.
Adaptive resistance has been previously described in bacterial
(Ferna´ndez et al., 2011) and fungal (Walker et al., 2010) systems
and likely surfaces in tumor cells based on their need to tolerate
the myriad stresses associated with their microenvironment and
unrestrained growth (proteotoxic, mitotic, oxidative, DNA dam-
age, andmetabolic) (Luo et al., 2009). The capacity of cells to un-
dergo adaptive resistance is rooted in cellular signaling and/or
transcriptional networks that involve feedback-dependent ho-
meostatic control (Chandarlapaty, 2012; Pisco et al., 2013),such as the mechanisms proposed to regulate k-MT attachment
stability during mitosis (Godek et al., 2015). Importantly, these
data suggest that the oncogenic pathways that drive cellular
transformation impose changes onto the signaling networks
that regulate chromosome segregation fidelity during mitosis
(Orr and Compton, 2013) to promote and preserve CIN. These
results provide insight into the observations that CIN cancer cells
frequently display multi-drug resistance (Lee et al., 2011) and
that the efficacy of targeted therapies based on molecular
profiling in tumor cells (Barretina et al., 2012; Garnett et al.,
2012) has been limited by rapid alterations of cellular signaling
and/or transcriptional networks responsible for generating
adaptive resistance (Litvin et al., 2015; Muranen et al., 2012;
Sun et al., 2014).
EXPERIMENTAL PROCEDURES
Drug Treatments
UMK57 was used for all assays at 100 nM (5-fold lower than the calculated
IC50 in U2OS cells) since this is the lowest concentration of UMK57 that results
in maximal suppression of lagging chromosomes and was used at 100–
2,000 nM for cell proliferation assays only. The following drugs were also
used: Monastrol (100 mM; Tocris Bioscience), MG132 (5 mM; Sigma-Aldrich),
paclitaxel (Taxol) (1–100 nM; Biotang), doxorubicin (1–100 nM; Sigma-Aldrich),
vinblastine (0.1-2 nM, Sigma-Aldrich), BI-2536 (2–500 nM; synthesized in-
house), ZM447439 (100–3,000 nM; Tocris Bioscience), and verapamil (6 mM;
Sigma-Aldrich). All controls for drug treatment were performed using 0.1%
DMSO.
Photoactivation Experiments
k-MT attachment stability was measured in U2OS cells expressing a-tubulin
tagged with photoactivatable GFP (plasmid provided by Alexey Khodjakov).
Differential interference contrast (DIC) microscopy was used to identify mitotic
cells, and fluorescent images were generated and acquired using Quorum
WaveFX- X1 spinning disk confocal system (Quorum Technologies) equipped
with Mosaic digital mirror for photoactivation (Andor Technology) and Hama-
matsu ImageEM camera. Cells were defined as being in prometaphase or
metaphase on the basis of chromosome alignment using DIC optics. Micro-
tubules were locally activated in one half-spindle. Fluorescence images
captured every 15 s for 4minwith a 1003 oil-immersion 1.4 numerical aperture
objective. To quantify fluorescence dissipation after photoactivation, mean
pixel intensities were quantified within a rectangular area surrounding the re-
gion of highest fluorescence intensity and background subtracted using an
equally sized area from the non-activated half-spindle using Quorum WaveFX
software. Fluorescence intensities were normalized to the first time point after
photoactivation for each cell following background subtraction and correction
for photobleaching. Correction for photobleaching was calculated by normal-
izing to values of fluorescence loss obtained from photoactivated 100 nM
Taxol-stabilized spindles where the photoactivated region did not dissipate.
To measure microtubule turnover, the average intensity at each time point
was fit to a double exponential curve A13 exp(k13 t) + A23 exp(k23 t) using
MATLAB (MathWorks), where t is time, A1 represents the less stable (non-k-
MT) population, and A2 represents the more stable (k-MT) population, with
decay rates of k1 and k2, respectively. When the equation for the double expo-
nential curve is solved, the rate constants as well as the percentage of micro-
tubules for the fast (non-k-MT) and slow (k-MT) processes are obtained.
The turnover half-life for each process was calculated as ln2/k for each
population of microtubules. All experiments were performed in the presence
of MG132 (5 mM) to prevent mitotic exit.
Cell Transfections
Plasmid transfections were done with FuGENE 6 (Roche Diagnostics), and
cells were analyzed 24 hr later by immunofluorescence. Plasmids used were
GFP (pEGFP plasmid with modified multiple cloning site to incorporate AscICell Reports 17, 1755–1763, November 8, 2016 1761
and PacI sites; gift from Aaron Straight) and GFP-Kif2b and GFP-MCAK (gifts
from Linda Wordeman). Short interfering RNA (siRNA) transfections were
performed using Oligofectamine (Invitrogen), and cells were analyzed 48 hr
later. RNA duplexes for mock siRNA (Silencer Negative Control No. 4),
Kif2b (Silencer Select Pre-designed; 50-GGACCUGGAUAUCAUCACCtt-30),
or MCAK (Silencer Select Validated siRNA; 50-CAAAGUAUCUGGAGAAC
CAtt-30) were purchased from Ambion and used at a concentration of 200 nM.
Chromosome Mis-segregation Assay
To analyze chromosome segregation in interphase cells, cells were arrested in
mitosis with monastrol (100 mM) for 15 hr and then media replaced with media
containing DMSO or UMK57 (100 nM). Mitotic cells were isolated by shake-off
and plated at low density on coverslips for 8 hr (to allow cells to complete cyto-
kinesis and re-enter interphase). For fixing, cells were pre-extracted with
pre-warmed PHEM with 1% Triton X-100 for 5 min then fixed with 3.5%
paraformaldehyde. Cells stained with DAPI and mounted using ProLong
Gold antifade reagent (Molecular Probes).
CIN Assay
U2OS or RPE-1 cells plated at a low density (50–100 cells/plate) in 100-mm
plates, and single-cell clones were subsequently isolated and expanded grad-
ually until each clone occupied two 100-mm plates as a monolayer (6–8 weeks
for U2OS cells; 4–6 weeks for RPE-1 cells). Cells were then rinsed with PBS,
treated with KCl (75 mM) for 30 min, and fixed in and washed twice with meth-
anol-acetic acid (3:1). FISH was performed using centromeric a-satellite
probes for chromosomes 2 and 3 (Cytocell) according to manufacturer’s
instructions.
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